Assuming patients is required, the following results were found.

  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) DetailsHits: 158If approved, Mayzent® (siponimod) will be the first and only oral treatment...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) Details Hits: 158 If approved, Mayzent® (siponimod) will be the first and only oral...

    https://mschristian.org/index.php/articles/2-uncategorised/9270-novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • "Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction"

    and immunopathogenesis and instead share some clinical pearls to help both simplify and advance your care for patients and families affected by MS. My goal is to share a simple approach that will serve you and your patients well, with the aim of helping...

    https://mschristian.org/index.php/blog/treating-ms-a-simplified-strategy-boosts-patient-and-provider-satisfaction
  • DOUBT Study Clarifies Role of MRI for TIA or Stroke

    (MRI). Question Addressed: What was the rate of stroke defined by diffusion restriction detected on MRI scans among patients with low-risk suspected transient ischemic attack (TIA) or minor stroke presentations? Study Synopsis and Perspective: Patients...

    https://mschristian.org/index.php/blog/doubt-study-clarifies-role-of-mri-for-tia-or-stroke
  • Demyelinating Risks With Anti-TNF Vary in Rheumatic Diseases - MedPage Today

    Patients with certain types of arthritic conditions were at elevated risk for developing neuroinflammatory events if treated with tumor necrosis factor (TNF) inhibitors, a large prospective cohort study conducted in Denmark and Sweden found. Among...

    https://mschristian.org/index.php/blog/demyelinating-risks-with-anti-tnf-vary-in-rheumatic-diseases-medpage-today
  • DOUBT Study Clarifies Role of MRI for TIA or Stroke

    (MRI). Question Addressed: What was the rate of stroke defined by diffusion restriction detected on MRI scans among patients with low-risk suspected transient ischemic attack (TIA) or minor stroke presentations? Study Synopsis and Perspective: Patients...

    https://mschristian.org/index.php/articles/2-uncategorised/8834-doubt-study-clarifies-role-of-mri-for-tia-or-stroke
  • First Report of COVID-19 Neurologic Symptoms in China

    symptoms, researchers said. Acute cerebrovascular events, impaired consciousness, and muscle injury were seen in 36.4% of patients and were more common (45.5%) in patients with severe infection who required mechanical ventilation, reported Bo Hu, MD,...

    https://mschristian.org/index.php/blog/first-report-of-covid-19-neurologic-symptoms-in-china
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    Inc., (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the third quarter of 2019 and recent...

    https://mschristian.org/index.php/blog/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • First Report of COVID-19 Neurologic Symptoms in China

    symptoms, researchers said. Acute cerebrovascular events, impaired consciousness, and muscle injury were seen in 36.4% of patients and were more common (45.5%) in patients with severe infection who required mechanical ventilation, reported Bo Hu, MD,...

    https://mschristian.org/index.php/articles/2-uncategorised/10546-first-report-of-covid-19-neurologic-symptoms-in-china
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    Inc., (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the third quarter of 2019 and recent...

    https://mschristian.org/index.php/articles/2-uncategorised/9192-atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Rethinking neurodegenerative disease treatment: Target multiple pathological proteins

    all of the different neurodegenerative disorders and may instigate each other to drive disease severity in many aging patients. The prevalence of these co-pathologies suggests that each disease may ultimately require combination therapy targeting...

    https://mschristian.org/index.php/blog/rethinking-neurodegenerative-disease-treatment-target-multiple-pathological-proteins
  • COVID-19 and Neuromyelitis Optica Disorder: A Need for Guidance-Based Management - Neurology Advisor

    disease 2019 (COVID-19) pandemic continues to unfold and healthcare workers scramble to meet demands of affected patients, little guidance has been issued on how to manage patients with COVID-19 and coexisting neurological disorders. In a recent paper...

    https://mschristian.org/index.php/blog/covid-19-and-neuromyelitis-optica-disorder-a-need-for-guidance-based-management-neurology-advisor
  • Short-Duration Opioid Protocol Feasible for Tonsillectomy

    within the first year after surgery, a retrospective analysis of active-duty military personnel showed. Of almost 700 patients who received as much as a 15-day postoperative prescription of opioid-containing medication, none had a referral for treatment...

    https://mschristian.org/index.php/blog/short-duration-opioid-protocol-feasible-for-tonsillectomy
  • MS Patients Have Low Blood Levels of Infection-fighting Antibodies, Study Finds - Multiple Sclerosis News Today

    infection. Because many MS therapies work by decreasing the activity of the immune system, it is possible that treated patients have abnormally low levels of certain kinds of antibodies and, as a result, become more prone to infection. A team led by...

    https://mschristian.org/index.php/articles/2-uncategorised/9076-ms-patients-have-low-blood-levels-of-infection-fighting-antibodies-study-finds-multiple-sclerosis-news-today
  • CMSC INforMS: Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says

    20 years ago, according to a retrospective study. The study, “Outcomes in a Modern Cohort of Treated Multiple Sclerosis Patients Followed from Diagnosis Up to 15 Years,” was published in the International Journal of MS Care. “Before disease-modifying...

    https://mschristian.org/index.php/blog/cmsc-informs-use-of-dmts-changing-natural-history-of-relapsing-ms-study-says
  • Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

    (OA) -- good enough that this agent may finally be approved after a long and rocky development road. Among 849 patients enrolled from 104 sites from 2016 to 2018 who had not responded to other oral or injectable treatments, those randomized to 5-mg...

    https://mschristian.org/index.php/blog/tanezumab-a-win-as-last-ditch-osteoarthritis-tx
  • FDA Approves Bafiertam, (a Tecfidera) Generic, for Relapsing MS

    of relapsing forms of multiple sclerosis (MS). “The FDA’s final approval marks an important milestone for Banner and for patients living with relapsing-remitting multiple sclerosis,” said Franck Rousseau, M.D., Chief Executive Officer of Banner. “We are...

    https://mschristian.org/index.php/blog/fda-approves-bafiertam-a-tecfidera-generic-for-relapsing-ms
  • Antiviral cocktail may help treat mild COVID-19 patients

    Now, a team of researchers in Hong Kong suggests that combining three existing antivirals may help treat COVID-19 patients. The team has found that patients experiencing mild symptoms caused by the novel coronavirus recover faster if they are treated...

    https://mschristian.org/index.php/antiviral-cocktail-may-help-treat-mild-covid-19-patients
  • Suicide Rate Almost Double in Patients With MS

    BARCELONA — Patients with multiple sclerosis (MS) are more than twice as likely as the general population to attempt suicide and almost twice as likely to actually complete suicide, a new study shows. The study also had some interesting results with...

    https://mschristian.org/index.php/blog/suicide-rate-almost-double-in-patients-with-ms
  • "Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction"

    and immunopathogenesis and instead share some clinical pearls to help both simplify and advance your care for patients and families affected by MS. My goal is to share a simple approach that will serve you and your patients well, with the aim of helping...

    https://mschristian.org/index.php/articles/2-uncategorised/9438-treating-ms-a-simplified-strategy-boosts-patient-and-provider-satisfaction

Results 1 - 20 of 451